MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: spasticity"

  • 2019 International Congress

    OnabotulinumtoxinA treatment in adults with spasticity reduces caregiver burden: Results from the ASPIRE study

    A. Esquenazi, A. Ellenbogen, G. Wittenberg, K. Ngo, J. Largent, A. Zuzek, G. Francisco, W. Jost (Elkins Park, PA, USA)

    Objective: To examine the impact of onabotulinumtoxinA treatment in adult patients with spasticity on caregiver burden over 2 years from the Adult Spasticity International Registry…
  • 2019 International Congress

    Clinical Characteristics that Impact OnabotulinumtoxinA Treatment Adherence in Patients with Spasticity from ASPIRE

    A. Esquenazi, W. Feng, G. Wittenberg, P. Gallien, A. Baricich, K. Fanning, A. Zuzek, G. Francisco, D. Bandari (Elkins Park, PA, USA)

    Objective: To identify patient demographics and clinical characteristics that impact onabotulinumtoxinA treatment adherence from the Adult Spasticity International Registry (ASPIRE) study. Background: A better understanding…
  • 2019 International Congress

    An examination of real-world onabotulinumtoxinA utilisation for the treatment of lower limb spasticity: The Adult Spasticity International Registry (ASPIRE) study

    A. Esquenazi, W. Jost, G. Bavikatte, D. Bandari, M. Munin, A. Zuzek, A. Patel, J. Largent, G. Francisco (Elkins Park, PA, USA)

    Objective: To explore real-world patterns of onabotulinumtoxinA utilisation in patients with lower limb spasticity over 2 years. Background: OnabotulinumtoxinA treatment for spasticity is variable as…
  • 2019 International Congress

    Goal setting for botulinum toxin injections: Impact of the Upper Limb International Spasticity (ULIS) programme

    K. Fheodoroff, S. Ashford, J. Jacinto, A. Brashear, P. Maisonobe, A. Lysandropoulos, L. Turner-Stokes (Hermagor, Austria)

    Objective: The Upper Limb International Spasticity (ULIS) programme is a series of observational cohort studies across >30 countries. This analysis explores changes in goal setting…
  • 2019 International Congress

    AbobotulinumtoxinA: evidence for long duration of response

    K. Foster, A. Lysandropoulos, P. Picaut (Abingdon, United Kingdom)

    Objective: To assess clinical treatment intervals and duration of response for abobotulinumtoxinA in the management of pediatric and adult spasticity and assess preclinical data that…
  • 2019 International Congress

    An examination of real-world onabotulinumtoxinA utilization for the treatment of upper limb spasticity: The Adult Spasticity International Registry (ASPIRE) study

    G. Francisco, G. Bavikatte, W. Jost, D. Bandari, S. Tan Tang, A. Zuzek, A. Patel, J. Largent, A. Esquenazi (Taoyuan, Taiwan)

    Objective: To explore real-world patterns of onabotulinumtoxinA utilization in patients with upper limb spasticity over 2 years. Background: OnabotulinumtoxinA treatment for spasticity is variable, as…
  • 2019 International Congress

    OnabotulinumtoxinA Reduces Disability in Treatment-Naive Adult Patients with Spasticity: Results from the ASPIRE Study

    W. Jost, A. Ellenbogen, G. Wittenberg, K. Ngo, J. Largent, A. Zuzek, G. Francisco, A. Esquenazi (Irvine, CA, USA)

    Objective: Examine real-world onabotulinumtoxinA utilization and effectiveness over 2 years in patients naive or non-naive to botulinum toxins for spasticity from the Adult Spasticity International…
  • 2019 International Congress

    Successful late rehabilitation based on botulinum therapy

    T. Kuznetsova, A. Svetkina (Samara, Russian Federation)

    Objective: Hemiparesis of various severity is the most common stroke side effect. On average 30-40% of stroke survivors develop post-stroke spasticity. The best neuroplasticity enabling…
  • 2019 International Congress

    Training and Usage of Botulinum Neurotoxin-A Guided Injection in Cervical Dystonia & Spastic Paresis: results from the INPUT survey

    R. Bhidayasiri, K. Bhatia, LJ. Jacinto, TM. Chung, A. Fulford-Smith, C. Colosimo (Roma, Italy)

    Objective: To describe the current situation of training and practices among physicians using guidance techniques for botulinum neurotoxin-A (BoNT-A) injectionsin the treatment of Cervical Dystonia…
  • 2019 International Congress

    Ixcellence Network®, an International Innovative Educational Programme To Improve Cervical Dystonia And Spastic Paresis Management: Feedback survey from 839 attendees

    C. Colosimo, TM. Chung, LJ. Jacinto, K. Bhatia, A. Fulford-Smith, R. Bhidayasiri (Roma, Italy)

    Objective: To assess the Ixcellence Network® training programme educative quality and impact on physicians using botulinum neurotoxin-A (BoNT-A) in cervical dystonia (CD) and spastic paresis…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley